Neomycin is primarily used to treat and manage hepatic coma and perioperative prophylaxis. It belongs to the aminoglycosides group of antibiotics, which function by inhibiting bacterial protein synthesis, resulting in a bactericidal effect primarily against gram-negative bacteria. Neomycin is also used topically for minor skin infections and in combination therapies for bowel sterilization before surgical procedures. It is available in various formulations, including oral tablets, topical creams, and ointments.
Parent: Neomycin / Framycetin / Paromomycin
Parent: Neomycin/ Framycetin / Paromomycin
Parent: Neomycin Sulfate/ Neomycin
During the production and storage of Neomycin, related compounds and impurities may form, which must be controlled to ensure the medication’s safety and efficacy. Regulatory guidelines specify permissible impurity levels to maintain the quality of Neomycin products.
Key aspects of Neomycin-related compounds and impurities include:
Advanced analytical techniques, such as High-Performance Liquid Chromatography (HPLC), are used to detect and quantify Neomycin-related compounds and impurities, ensuring compliance with stringent safety and quality standards.
Neomycin has not been universally discontinued but its use has declined in some regions due to its potential for nephrotoxicity (kidney damage) and ototoxicity (hearing damage). It is now mainly reserved for specific indications such as hepatic encephalopathy and perioperative prophylaxis.
Neomycin is effective primarily against gram-negative bacteria. It inhibits bacterial protein synthesis, leading to cell death. However, it has limited activity against gram-positive bacteria and anaerobes.
Neomycin should not be taken by individuals with a known hypersensitivity to aminoglycosides, preexisting kidney impairment, or intestinal obstruction. It is also contraindicated in patients with conditions that increase the risk of hearing loss due to its ototoxic potential.
The choice between Neomycin and Erythromycin depends on the type of infection and the bacteria involved. Neomycin is more effective against gram-negative bacteria, while Erythromycin, a macrolide antibiotic, has broader coverage, including gram-positive bacteria and atypical pathogens. A healthcare provider should determine the most appropriate treatment based on the specific infection.
